2659results about "Compound screening" patented technology

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides for the treatment of aging, senescence, fibrosis, metabolic diseases, cardiovascular diseases, endocrine-related disorders, genetic diseases, cancer, infections, immune diseases, and the like using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein. Methods of replacing an adaptation of therapy or combinations thereof with hormones, growth factors and / or proteins, as well as methods of identifying the agents.

The invention belongs to the field of cosmetic detection, and discloses a cosmetic and cosmetic raw material sunscreen function evaluation method and application. According to the evaluation method, a sunscreen effect test is carried out on a test sample by using a non-contact administration device, wherein the test sample is a cosmetic finished product or a diluted cosmetic raw material; the test comprises evaluation of in-vitro sunscreen effect by skin cells, evaluation of in-vivo sunscreen effect by a zebra fish embryo model and result evaluation. According to the method, the sunburn-resistant effect is evaluated through expression of beta-galactosidase in human dermal fibroblasts and / or secretion of collagen, the sunburn-resistant effect is evaluated through the survival rate of human keratinocytes, the DNA damage condition or inflammatory factor secretion and the lethal / teratogenic condition of zebra fish embryos, and multi-layer and all-around sunburn-resistant effect evaluation is achieved. The method provided by the invention is suitable for evaluating the sunscreen function of various sunscreen products, has accuracy and practicability, and provides an important technical basis for research and development, quality control and performance optimization of sunscreen cosmetics.

The invention discloses a personalized in-vitro total digestion glycolysis simulation system, and belongs to the technical field of in-vitro digestion simulation. According to the invention, by dynamically regulating and controlling the emptying amount and the flow velocity of digestive juice, the process of'digesting and absorbing at the same time 'in the small intestine is simulated, and the interaction of colon flora and colon organs is enhanced in combination with a micro-fluidic chip technology, so that the accurate detection of the digestion process and digestion products is realized. The digestion product simulated by the method disclosed by the invention and the flora structure are very close to the real in-vivo structure, so that the method has relatively high authenticity and credibility.

The present invention provides methods of screening for compounds that interfere with the interaction between ERG. ETV1, ETV4 or ETV5 and mSWI / SNF (BAF) chromatin remodeling complex proteins. Included are methods of screening for compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and BAF155. Methods of treating prostate cancer with compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and mSWI / SNF (BAF) chromatin remodeling complex proteins are also provided.

The invention relates to the technical field of cytology, in particular to a grass carp brain astrocyte line and application thereof, the grass carp brain astrocyte line is preserved in China Center for Type Culture Collection on May 7, 2025, and the preservation number of the grass carp brain astrocyte line is CCTCC NO: C2025149. The grass carp brain astroglia cell line provided by the invention has the capability of efficiently proliferating GCRV-II, and the virus titer of the GCRV-II replicated in the cell line at least can reach 1.38 * 10 < 8 > pfu / mL or above; after the GCRV-II is blindly passed for 5 generations in a grass carp astroglia cell line, the grass carp can still have typical bleeding symptoms and death due to the virus. And the exogenous plasmid transfected grass carp brain astroglia cell line has similar transfection efficiency to commercial grass carp kidney cells. Therefore, the invention lays an important foundation for deep research of pathogenic mechanism of GCRV-II, vaccine preparation, antiviral drug screening and prevention and control of grass carp viral hemorrhagic disease.

The invention belongs to the technical field of biological medicines, and provides application of DRAM1 as a diagnosis and treatment target for resisting non-alcoholic fatty liver disease related hepatocellular carcinoma in preparation of a kit, a carrier and a medicine aiming at the problem of lack of effective treatment targets of NAFLD-related HCC. As a target spot for resisting the non-alcoholic fatty liver disease related hepatocellular carcinoma, the expression level of the DRAM1 in liver tissues of non-alcoholic fatty liver disease related hepatocellular carcinoma patients and mice is increased. According to the application disclosed by the invention, research is developed aiming at the effect of the DRAM1 in the generation and development of NAFLD-related HCC, the analysis of TCGA liver cancer queue data and a GSE164760 data set is taken as an entry point, the influence of the DRAM1 on the diagnosis and prognosis of the liver cancer is comprehensively analyzed, and verification is carried out through a mouse in-vivo experiment, so that a new thought and a new target spot are provided for clinical diagnosis and treatment of the liver cancer.

The invention relates to a heart organoid and an in-vitro preparation method thereof, and belongs to the technical field of stem cells. The invention provides a heart organoid. The heart organoid is obtained by induced culture of an adherent pluripotent stem cell mass; the adherent pluripotent stem cell mass is obtained by adherent culture of a suspended pluripotent stem cell mass; the suspension pluripotent stem cell mass is obtained by suspension culture of pluripotent stem cells. According to the in-vitro preparation process of the heart organoid, after pluripotent stem cells form balls, the pluripotent stem cell balls are subjected to staged induced differentiation under adherent culture, so that cell subtypes such as epicardial cells and the like can be generated without additional addition or additional stimulation of signal channels, and the heart organoid is more homogeneous. The self-occurring multi-lineage coexisting heart organoid can better simulate biological events derived from multiple cell types and multiple cell subtypes in the early development process of an embryonic heart, and has great application prospects in exploration of pathogenic factors and potential treatment targets of congenital heart diseases.

The invention belongs to the technical field of tissue engineering, and particularly discloses a preparation method of a 3D full-thickness skin model. The preparation method provided by the invention comprises the following steps: constructing a corium layer, constructing an inner epidermal layer through first epidermal inoculation, constructing an epidermal layer through second epidermal inoculation and obtaining a complete 3D full-thickness skin model through co-culture. The 3D full-thickness skin model obtained through the preparation method is distinct in gradation, uniform in thickness, free of shrinkage and stable in quality, the epidermal layer and the corium layer are uniformly fused, and the 3D full-thickness skin model is suitable for skin function research and sample evaluation. Meanwhile, the preparation method provided by the invention is simple in process and convenient to operate, does not need additional reagents or anti-shrinkage tools, can meet the requirements of large-scale industrial production, and has good production feasibility and market application prospects.

Provided are an anti-BCMA single-domain antibody, and a preparation method therefor and the use thereof. Specifically, provided is a single-domain antibody having an amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity, can thoroughly specifically target BCMA-positive cells, and can be applied to the detection of BCMA expression in bone marrow cells of MM patients. The single-domain antibody can be prepared into a specific antibody drug clinically used for preventing and treating BCMA-target-related diseases (such as multiple myeloma, B-cell acute lymphoblastic leukemia, non-Hodgkin's lymphoma and Hodgkin's lymphoma); or a BCMA protein detection kit, etc. The single-domain antibody has a stable structure, a small molecular size, is easily recombinantly expressed and has a low production cost, can be used alone or as a drug delivery system to carry relevant drugs, and has very wide prospects and important significance in fields such as drug application and clinical diagnosis.

The present invention belongs to the field of cosmetics detection, and discloses a method for evaluating the sun protection function of cosmetics and cosmetic raw materials and its application. This evaluation method uses a non-contact drug delivery device to test the sun protection effect of the test samples, and the test samples are finished cosmetics or diluted cosmetic raw materials; the tests include evaluating the in vitro sun protection efficacy by skin cells, evaluating the in vivo sun protection efficacy by the zebrafish embryo model, and result evaluation. This method evaluates the anti-aging effect of sun protection through the expression of β-galactosidase and / or the secretion of collagen in human dermal fibroblasts, and evaluates the sunburn prevention effect through the survival rate of human keratinocytes, DNA damage, or the secretion of inflammatory factors and the lethal / teratogenic conditions of zebrafish embryos, realizing multi-level and all-round evaluation of the sun protection efficacy. The method provided by the present invention is applicable to the evaluation of the sun protection function of various sun protection products, has accuracy and practicability, and provides an important technical basis for the research and development, quality control, and performance optimization of sun protection cosmetics.

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides methods of treating aging, senescence, fibrosis, autoimmunity, cancer, infection, and / or immune disease using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein, as well as methods of identifying the agents.

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein. In some embodiments, the target and / or presenter proteins are intracellular proteins. In some embodiments, the target and / or presenter proteins are mammalian proteins.

The present invention relates to a screening method for odor-suppressing materials. A screening method according to the present invention includes: causing a test substance and an odor-causing substance to act on at least one olfactory receptor polypeptide selected from the group consisting of olfactory receptor OR2AG2 and polypeptides that include an amino acid sequence having 80% or greater identity with the amino acid sequence of the aforementioned olfactory receptor and exhibit responsiveness to odor-causing substances; measuring the response of the olfactory receptor polypeptide to the odor-causing substance; and, on the basis of the measured response, identifying test substances that suppress a response of the olfactory receptor polypeptide as candidate substances for an odor-suppressing material.

Disclosed herein are methods for identifying novel drug candidates.

The invention discloses application of MIGA2 as a therapeutic target in a medicine for preventing and treating Alzheimer's disease, and belongs to the technical field of biological medicine. The MIGA2 gene is used as a therapeutic target to be applied to development, screening or preparation of drugs for preventing and treating Alzheimer's disease. After an MIGA2 overexpression plasmid is adopted to transfect an Alzheimer's disease cell model, it is found that autophagy flow in cells can be promoted and accumulation of related toxic proteins can be reduced, it is proved that MIGA2 has the neuroprotective effect on the Alzheimer's disease, and a new way and exploration direction are provided for treatment of the Alzheimer's disease.

The invention discloses a breast adenoma B3 type source cell strain as well as construction and application thereof, the breast adenoma B3 type source cell strain is named as human breast adenoma cell Hthy2301 Homo sapiens and is preserved in China Center for Type Culture Collection on March 14, 2024, and the preservation number is CCTCC NO: C202478. The human thymoma cell line is stable in character, can be passaged in vitro for a long time, and has high proliferation activity. The human thymoma cell line disclosed by the invention can be used as an effective cell model, and a new experimental model can be provided for deeply researching the occurrence, development and transfer mechanisms of thymoma, the drug resistance mechanism, drug screening, drug effect evaluation and the like.

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TEM3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

The invention relates to a cochlea spiral neuron in-vitro organ as well as a construction method and application thereof, and provides a method for obtaining a mature inner ear neuron by utilizing human pluripotent stem cell differentiation in vitro and further constructing an inner ear neuron in-vitro organ on the basis of the mature inner ear neuron. The internal ear neuron in-vitro organoid function stage obtained by the method and the application thereof are also provided.

Provided herein are methods of activating immune response and / or treating cancer in a patient comprising administering to the patient a Gal3:TIM-3 inhibitor that interferes with the interaction between Gal3 and TIM-3, where said inhibitor is administered in an amount sufficient to activate immune response. Also provided are a humanized anti-Gal3 antibodies that can block the interaction between Gal3 and TIM3 and methods of using the anti-Gal3 antibody to treat cancer. Methods for determining if a patient's cancer is suitable for treatment with a Gal3:TIM-3 inhibitor and methods for selecting compounds that can block interaction between Gal3 and TIM-3, activating immune response and / or treating cancer are also provided.

The invention relates to a cell collection method capable of simultaneously collecting three cells in a co-culture model, and belongs to the technical field of biology. The invention provides a cell collection method capable of simultaneously collecting three cells in a co-culture model, and the cell collection method comprises the following steps: after a three-cell co-culture model is constructed, taking out a Transwell chamber, retaining cells in the lower chamber, and collecting the cells in the lower chamber; respectively digesting the cells on the two sides of the Transwell cell membrane by using a trypsin solution with the concentration of 0.5 g / 100mL so as to respectively collect the cells on the two sides of the Transwell cell membrane. According to the cell collection method disclosed by the invention, the three cells in the three-cell co-culture model are simultaneously collected in a manner of digesting the cells on the two sides of the Transwell membrane step by step by using pancreatin, so that not only is the cell and consumable cost saved, but also the experimental synchronism of the three cells is ensured, and convenience is provided for optimizing the experimental process.

The invention discloses an inflammatory bowel disease model, a construction method and application thereof and a drug evaluation method based on the inflammatory bowel disease model, and belongs to the technical field of inflammatory bowel disease model construction. A highly bionic intestinal crypt-villus three-dimensional structure is formed based on self-organization of an intestinal cell line C2BBe1, the intestinal crypt-villus three-dimensional structure and a DMEM complete medium containing dextran sulfate sodium are added into an upper chamber of a double-layer culture chamber Transwell, the DMEM complete medium is added into a lower chamber of the double-layer culture chamber Transwell, culture is performed for 2 days, and the inflammatory bowel disease model is obtained. The method takes effect quickly and is highly simulated, the obtained model can simulate the space-time dynamic development process of intestinal inflammation molecular characteristics, and the natural recovery model and the drug treatment model constructed based on the model can provide a brand new platform for researching an inflammation regression mechanism and a drug intervention effect.

To provide a method for evaluating disposition and / or effect of a candidate compound in an in-vitro culture and / or suspension to predict in-vivo disposition and / or effect of the candidate compound.SOLUTION: A method comprises the steps of: providing a cell culture and / or suspension; exposing a candidate compound to the culture and / or suspension; exposing the culture and / or suspension to a culture medium providing an extracellular environment related to in vivo (the culture medium contains a certain component (e.g., protein or the like) at a concentration having characteristics (e.g., binding characteristics) similar to physiological concentration or physiologic concentration), wherein arbitrary combination of any of the "exposing steps" can occur in any order or simultaneously; and evaluating in-vitro disposition and / or effect of the candidate compound to predict in-vivo disposition and / or effect of the candidate compound.SELECTED DRAWING: None

The invention discloses a cell and a method for detecting the activity of a GLP-1R / GIPR double-target agonist drug. The invention relates to a cell for co-expressing GLP-1R, GIPR and CRE-miniP-luciferase reporter genes, and provides a method for detecting the biological activity of a GLP-1R / GIPR double-target agonist drug based on the cell, and the method is simple to operate, short in test period, sensitive in reaction, small in variability, strong in specificity and high in accuracy, can be used for release inspection of products, and can be used for detecting the biological activity of the GLP-1R / GIPR double-target agonist drug. The method has important significance on quality control and clinical application of GLP-1R / GIPR double-target agonist drugs.

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

The invention discloses an NF (nuclear factor)-kappa B inhibitor. The NF-kappa B inhibitor comprises N-trans-p-coumaroyl tyramine; the invention further discloses a preparation method of the NF-kappa B inhibitor. The invention also discloses an application of the NF-kappa B inhibitor in medicines for preventing or treating diseases related to body inflammation. According to the application disclosed by the invention, the influence of the N-trans-p-coumaroyl tyramine on a TLR4 / MyD88 / NF-kappa B inflammation signal channel is detected through an immunofluorescence technology, and a result shows that the N-trans-p-coumaroyl tyramine can be used for reducing the expression of TLR4 and MyD88 proteins and inhibiting the transfer of NF-kappa B proteins to cell nucleuses, so that the N-trans-p-coumaroyl tyramine can be used as an NF-kappa B inhibitor and can be used for preparing an anti-inflammatory drug. The composition is used for preventing or treating body inflammatory response.

Provided are a method and the like for efficiently screening for a candidate substance for a starting material that suppresses hexanal odor. The screening method according to the present invention comprises the steps of: adding a test substance and hexanal to a specific olfactory receptor polypeptide; a step for measuring the response of the olfactory receptor polypeptide to hexanal; and identifying, on the basis of the measured response, a test substance that inhibits the response of the olfactory receptor polypeptide as a candidate substance for a raw material that inhibits hexanal odor.

Some methods of performing an assay comprise culturing target cells in one or more channels of one or more microfluidics chips, where each of the channel(s) can have a volume that is less than or equal to 100 microliters (μL). For each of one or more test liquids that each comprise a therapeutic reagent, the test liquid can flow over the cultured target cells in at least one of the channel(s) and, while the test liquid flows over the cultured target cells, data indicative of an interaction between the target cells over which the test liquid flows and the therapeutic reagent of the test liquid can be captured.

The invention discloses a lung squamous cell carcinoma drug discovery method and system based on disturbance response scanning analysis, and belongs to the field of biological medicines.The method comprises the steps that lung squamous cell carcinoma protein expression profile data is downloaded and preprocessed, a robust network module is constructed and multi-scale analysis and evaluation are conducted, and drug genomic data are obtained based on drug genomic data. Predicting the drug sensitivity of the patient by using machine learning, and generating a DRN through difference analysis of the drug sensitivity; predicting drug-target protein binding affinity in combination with deep learning, quantifying node sensitivity through a PRS technology, calculating a DPI disturbance score and ranking drug priorities; high-ranking drugs are screened through comprehensive sensitivity analysis and literature investigation; a drug for a lung squamous carcinoma cell line is screened out through a pre-experiment and is relocated. According to the framework developed by the invention, by integrating proteomics, pharmacogenomics and dynamic network analysis, systematic analysis is provided for relocation drug identification of lung squamous cell carcinoma, and good news is brought to treatment of lung squamous cell carcinoma.

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.